Replimune Group (REPL) Stock Price, Quote, News & History | Benzinga

Replimune Group Inc (REPL) Stock Price, Quote, News & History

REPLNASDAQ

Trade with Public

Trade with Public

$13.67

1.6113.35%

At close: Aug 7, 5:00 PM EST

$13.70

1.6413.6%

Pre-Market: 4:09 AM EST

PRO

Why Is It Moving?™:Replimune Group shares are trading higher. The company anounced the pricing...

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$13.67

Volume / Avg.

1.70K / 6.58M

Day Range

- - -

52 Wk Range

1.50 - 14.12

Market Cap

$1.15B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

64

Short Interest

49.77%

Days to Cover

9.44

Recent Replimune Group, Inc. News

Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment

FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanced cutaneous melanoma.

Vandana Singh

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinions and price targets for these stocks.

Avi Kapoor

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote

FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.

Vandana Singh

Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.

Avi Kapoor

This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See what other analysts think about these stocks.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-280.34M

Investing Cash Flow (TTM)

310.84M

Financing Cash Flow (TTM)

66.29M

Free Cash Flow (TTM)

-284.57M

Capital Expenditure (TTM)

-4.22M

Net Change in Cash (TTM)

96.79M

Analyst Trends and Forecast

3

2

Apr

2

Jun

1

1

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.2

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$991.33M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

6.91

Earnings Yield % (TTM)

-24.73%

Earnings Yield % (FWD)

-19.82%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.98

Company Debt

Total Debt

$83.31M

LT Debt

$83.31M

LT Debt Issuance (TTM)

$35.00M

LT Debt Repayment (TTM)

-$736.00K

Total Cash

$209.02M

Debt to Equity

0.67

Issuance of Debt (TTM)

$34.26M

Repayment of Debt (TTM)

-$736.00K

Key Statistics

Open

-

Close

$13.67

Volume / Avg.

1.70K / 6.58M

Day Range

- - -

52 Wk Range

1.50 - 14.12

Market Cap

$1.15B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

64

Short Interest

49.77%

Days to Cover

9.44

About

Sector

Health Care

Industry

Biotechnology

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic imm...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Replimune Group (REPL) stock?

A

You can purchase shares of Replimune Group (NASDAQ:REPL) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Replimune Group (REPL) competitors?

A

Other companies in Replimune Group’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Replimune Group (REPL) stock?

A

Replimune Group has a consensus price target of $12.88.

Q

What is the current price for Replimune Group (REPL)?

A

The stock price for Replimune Group (NASDAQ: REPL) is $13.7 last updated August 11, 2026 at 2:33 AM EDT.

Q

Does Replimune Group (REPL) pay a dividend?

A

There are no upcoming dividends for Replimune Group.

Q

When is Replimune Group (NASDAQ:REPL) reporting earnings?

A

Replimune Group does not have any upcoming earnings scheduled.

Q

Is Replimune Group (REPL) going to split?

A

There is no upcoming split for Replimune Group.

Q

What sector and industry does Replimune Group (REPL) operate in?

A

Replimune Group is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.